» Articles » PMID: 15647192

Exon 3 Beta-catenin Mutations Are Specifically Associated with Colorectal Carcinomas in Hereditary Non-polyposis Colorectal Cancer Syndrome

Overview
Journal Gut
Specialty Gastroenterology
Date 2005 Jan 14
PMID 15647192
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Activating beta-catenin mutations in exon 3 have been implicated in colorectal tumorigenesis. Although reports to the contrary exist, it has been suggested that beta-catenin mutations occur more often in microsatellite unstable (MSI+) colorectal carcinomas, including hereditary non-polyposis colorectal cancer (HNPCC), as a consequence of defective DNA mismatch repair. We have analysed 337 colorectal carcinomas and adenomas, from both sporadic cases and HNPCC families, to provide an accurate assessment of beta-catenin mutation frequency in each tumour type.

Methods: Direct sequencing of exon 3 of beta-catenin.

Results: Mutations were rare in sporadic (1/83, 1.2%) and HNPCC adenomas (1/37, 2.7%). Most of the sporadic adenomas analysed (80%) were small (<1 cm), and our data therefore differ from a previous report of a much higher mutation frequency in small adenomas. No oncogenic beta-catenin mutations were identified in 34 MSI+ and 78 microsatellite stable (MSI-) sporadic colorectal cancers but a raised mutation frequency (8/44, 18.2%) was found in HNPCC cancers; this frequency was significantly higher than that in HNPCC adenomas (p=0.035) and in both MSI- (p<0.0001) and MSI+ (p=0.008) sporadic cancers. Mutations were more common in higher stage (Dukes' stages C and D) cancers (p=0.001).

Conclusion: Exon 3 beta-catenin mutations are associated specifically with malignant colorectal tumours in HNPCC; mutations appear not to result directly from deficient mismatch repair. Our data provide evidence that the genetic pathways of sporadic MSI+ and HNPCC cancers may be divergent, and indicate that mutations in the HNPCC pathway of colorectal tumorigenesis may be determined by selection, not simply by hypermutation.

Citing Articles

EEPD1 is identified as a predictor of prognosis and immune microenvironment through pan-cancer analysis and related to progression of colorectal cancer.

Guo Y, Li S, Shi Z, Chen B, Wan Z, Yu P Heliyon. 2024; 10(7):e29285.

PMID: 38633650 PMC: 11021989. DOI: 10.1016/j.heliyon.2024.e29285.


Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer.

Song Y, Kerr T, Sanders C, Dai L, Baxter S, Somerville B Front Oncol. 2023; 13:1223915.

PMID: 37746286 PMC: 10516605. DOI: 10.3389/fonc.2023.1223915.


A novel RIP1-mediated canonical WNT signaling pathway that promotes colorectal cancer metastasis via β -catenin stabilization-induced EMT.

Kang A, Kim J, Kim Y, Kang S, Oh S, Park J Cancer Gene Ther. 2023; 30(10):1403-1413.

PMID: 37500894 PMC: 10581897. DOI: 10.1038/s41417-023-00647-6.


Adherens junction proteins on the move-From the membrane to the nucleus in intestinal diseases.

Lessey L, Robinson S, Chaudhary R, Daniel J Front Cell Dev Biol. 2022; 10:998373.

PMID: 36274850 PMC: 9581404. DOI: 10.3389/fcell.2022.998373.


: A platform for anticancer drug discovery and personalized therapies.

Munnik C, Xaba M, Malindisa S, Russell B, Sooklal S Front Genet. 2022; 13:949241.

PMID: 36003330 PMC: 9393232. DOI: 10.3389/fgene.2022.949241.


References
1.
Akiyama Y, Nagasaki H, Yagi K, Nomizu T, Yuasa Y . Beta-catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary non-polyposis colorectal cancer patients. Cancer Lett. 2000; 157(2):185-91. DOI: 10.1016/s0304-3835(00)00486-9. View

2.
Samowitz W, Powers M, Spirio L, Nollet F, VAN Roy F, Slattery M . Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999; 59(7):1442-4. View

3.
Iino H, Simms L, Young J, Arnold J, Winship I, Webb S . DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut. 2000; 47(1):37-42. PMC: 1727981. DOI: 10.1136/gut.47.1.37. View

4.
Polakis P . Wnt signaling and cancer. Genes Dev. 2000; 14(15):1837-51. View

5.
Shitoh K, Furukawa T, Kojima M, Konishi F, Miyaki M, Tsukamoto T . Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability. Genes Chromosomes Cancer. 2000; 30(1):32-7. DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1065>3.0.co;2-i. View